Canada - English - Health Canada

glenmark pharmaceuticals canada inc. - ethinyl estradiol; norgestimate; norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol - tablet - 0.035mg; 0.18mg; 0.215mg; 0.035mg; 0.25mg; 0.035mg - ethinyl estradiol 0.035mg; norgestimate 0.18mg; norgestimate 0.215mg; ethinyl estradiol 0.035mg; norgestimate 0.25mg; ethinyl estradiol 0.035mg - contraceptives

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - previfem® (norgestimate/ethinyl estradiol tablets) and tri-previfem® (norgestimate/ethinyl estradiol tablets) are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . tri-previfem® (norgestimate/ethinyl estradiol tablets) is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. previfem® (norgestimate/ethinyl estradiol tablets) should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14)] . do not prescribe previfem® or tri-previfem® to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [s

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - previfem® (norgestimate/ethinyl estradiol tablets) and tri-previfem® (norgestimate/ethinyl estradiol tablets) are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . tri-previfem® (norgestimate/ethinyl estradiol tablets) is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. previfem® (norgestimate/ethinyl estradiol tablets) should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14)] . do not prescribe previfem® or tri-previfem® to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [s

United States - English - NLM (National Library of Medicine)

northstar rx llc - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norgestimate 0.18 mg - tri-linyah tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . tri-linyah is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. tri-linyah should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14)] . tri-linyah is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have cor

United States - English - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norgestimate 0.18 mg - ortho tri-cyclen lo tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . do not prescribe ortho tri-cyclen lo to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] have uncontrolled hypertension [see warnings and precautions (5.4)] have

Canada - English - Health Canada

novopharm limited - norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol - tablet - 0.180mg; 0.035mg; 0.215mg; 0.035mg; 0.250mg; 0.035mg - norgestimate 0.180mg; ethinyl estradiol 0.035mg; norgestimate 0.215mg; ethinyl estradiol 0.035mg; norgestimate 0.250mg; ethinyl estradiol 0.035mg - contraceptives

Canada - English - Health Canada

novopharm limited - norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol - tablet - 0.180mg; 0.035mg; 0.215mg; 0.035mg; 0.250mg; 0.035mg - norgestimate 0.180mg; ethinyl estradiol 0.035mg; norgestimate 0.215mg; ethinyl estradiol 0.035mg; norgestimate 0.250mg; ethinyl estradiol 0.035mg - contraceptives

Canada - English - Health Canada

janssen inc - norgestimate; ethinyl estradiol; norgestimate; ethinyl estradiol; ethinyl estradiol; norgestimate - tablet - 0.215mg; 0.035mg; 0.25mg; 0.035mg; 0.035mg; 0.18mg - norgestimate 0.215mg; ethinyl estradiol 0.035mg; norgestimate 0.25mg; ethinyl estradiol 0.035mg; ethinyl estradiol 0.035mg; norgestimate 0.18mg - contraceptives

United States - English - NLM (National Library of Medicine)

actavis pharma, inc - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norgestimate 0.25 mg - mononessa and trinessa tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies (14)] . trinessa is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. trinessa should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see clinical studies (14)] . do not prescribe mononessa or trinessa to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings

United States - English - NLM (National Library of Medicine)

a-s medication solutions - norgestimate (unii: c291hfx4dy) (norgestimate - unii:c291hfx4dy), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - mono-linyah tablets are indicated for use by females of reproductive potential to prevent pregnancy [see clinical studies ( 14)] . do not prescribe mono-linyah to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35[ see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past[see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies[see warnings and precautions (5.1)] have cerebrovascular disease[see warnings and precautions (5.1)] have coronary artery disease[see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)[see warnings and precautions (5.1)] have uncontrolled hypertension[see warnings an